Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (September 2026)
14 slides from Novo Nordisk A/s Class B's investor day presentation, Sep 21, 2026
Slide 1: Blood & endocrine disorders
Blood & endocrine disorders Habib Bennaceur CMD26 SVP, Blood & Endocrine Disorders Capital Markets Day 21 September
Slide 2: Forward-looking statements
2 Blood & endocrine disorders Forward-looking statements Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, the materials displayed and other information provided (orally or in writing) at this Capital Markes Day as well as written information released, shown, o
Slide 3: The blood & endocrine therapy area is an evolution of the rare disease legacy
3 Blood & endocrine disorders The blood & endocrine therapy area is an evolution of the rare disease legacy, and a key pillar of Novo’s strategy Novo is positioned to lead in blood and Rare disease business has built a foundation for growth towards 2030 ambition endocrine disorders and adjacencies R
Slide 4: The four focus areas of blood & endocrine disorders have clear leadership parameters
4 Blood & endocrine disorders The four focus areas of blood & endocrine disorders have clear leadership parameters Haemophilia Haemoglobinopathies Maintain leadership Gain leadership Sickle cel • Unmet need for reduction in breakthrough HwI ld ise • Opportunity to fill therapy gap in sickle cell ble
Slide 5: Class expansion of Sogroya represents a core strategic approach
5 Blood & endocrine disorders Class expansion of Sogroya® represents a core strategic approach for blood & endocrine disorders Novo’s short and long-acting GH Expanding Sogroya® within and beyond Strategic life cycle management of therapies are market leaders GHD Sogroya® GH volume market share Mark
Slide 6: Novo's haemophilia portfolio addresses all patient segments and remaining unmet need
6 Blood & endocrine disorders Novo’s haemophilia portfolio addresses all patient segments and remaining unmet need Novo has >40 years of presence across the haemophilia market People with haemophilia A still experience compromises with current standard of care Haemophilia with Haemophilia A Haemophi
Slide 7: The FRONTIER programme supports denecimig's potential as a high-efficacy, convenient therapy
7 Blood & endocrine disorders The FRONTIER programme supports denecimig’s potential as a high-efficacy, convenient therapy that makes switching seamless Denecimig has the potential to deliver FRONTIER 4 showed denecimig efficacy FRONTIER 5 demonstrated ease of direct durable protection extends to pa
Slide 8: Denecimig combines best-in-class profile with superior patient experience
8 Blood & endocrine disorders Denecimig combines best-in-class profile with superior patient experience for treating haemophilia A Denecimig combines best-in-class profile with superior patient experience for treating Next steps for denecimig haemophilia A Denecimig is optimised for potency Dosing
Slide 9: Sickle cell disease is a chronic, progressive disorder with a global burden
9 Blood & endocrine disorders Sickle cell disease is a chronic, progressive disorder with a global burden Sickle cell disease impacts ~8 million people globally Lifelong disease burden with limited therapeutic options Sickle cell disease prevalence per 100,000 people 0 - <3 3 - <10 Anaemia Vaso-occl
Slide 10: Etavopivat's best-in-class profile supports blockbuster potential in sickle cell disease
10 Blood & endocrine disorders Etavopivat’s best-in-class profile supports blockbuster potential in sickle cell disease Etavopivat has potential to be best-in- Etavopivat is first in a new class of drugs to show significant reduction of VOC rate and class disease-modifying therapy in SCD improvement
Slide 11: Novo aims to establish etavopivat as a new standard of care in sickle cell disease
11 Blood & endocrine disorders Novo aims to establish etavopivat as a new standard of care in sickle cell disease while expanding into other haemoglobinopathies Commercial priorities for etavopivat Future development of etavopivat Elevate global Establish etavopivat as Expand patient access Phase 3b
Slide 12: Phase 3-ready opportunity in PNH for zaltenibart
12 Blood & endocrine disorders Phase 3-ready opportunity in PNH for zaltenibart, with adjacent haemato-renal disorders providing further optionality Attractive market with strong growth Zaltenibart has pipeline-in-a-drug Lead programme in paroxysmal potential and strategic fit for Novo potential in
Slide 13: Blood disorder pipeline is built on selective growth assets and disciplined life cycle management
13 Blood & endocrine disorders Blood disorder pipeline is built on selective growth assets and disciplined life cycle management Blood disorder pipeline Key R&D focus areas 2026 2027 2028 Explore all modalities Denecimig (HA) US and EU decision Etavopivat (SCD) Regulatory submission Phase 3b Leverag
Slide 14: Blood and endocrine disorder therapy area is an attractive, profitable specialty area for Novo
14 Blood & endocrine disorders 1 2 3 Blood and endocrine disorder therapy area is Novo has the opportunity to lead in Blood and endocrine disorder therapy area is an attractive, profitable specialty area for haemophilia A and sickle cell disease with a key growth driver, aiming to achieve >+50% Novo